The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.
A. W. Tolcher
Consultant or Advisory Role - AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Adnexus (U); Ambit BioSciences (U); Amgen (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Bayer (U); BIND Biosciences (U); Biogen Idec (U); Curis (U); Dendreon (U); Dicerna (U); Endo Pharmaceuticals (U); Enzon (U); Exelixis (U); FivePrime (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); Insert Therapeutics (U); Intellikine (U); Johnson & Johnson (U); Merck (U); Micromet (U); Nektar (U); Novartis (U); Ortho Biotech (U); Otsuka (U); Pfizer (U); PPD Development (U); ProNAi (U); Regeneron (U); Sanofi (U); Santaris (U); Spectrum Pharmaceuticals (U); SuperGen (U); Symphogen (U); Vaccinex (U); Veeda Oncology (U)
Research Funding - Abbott Laboratories; Adnexus; Ambit BioSciences; Amgen; ArQule; Array BioPharma; Arresto; Astellas Pharma; AVEO; Azaya Therapeutics; Bayer; Biogen Idec; BiPar Sciences; Bristol-Myers Squibb; Calando; Centocor Ortho Biotech; Coronado Biosciences; Cougar Biotechnology; Curis; Cyclacel; Cylene; Daiichi Sankyo; Dendreon; Enzon; Exelixis; FivePrime; Genentech; Genta; GlaxoSmithKline; Hana BioSciences; Immunogen; Lilly; Merck; Merrimack; MethylGene; Millennium; Myrexis; Nektar; Nerviano; Novartis; OncoMed; Onyx; Ortho Biotech; Pfizer; PharmaMar; Proacta; ProNAi; Provia Biologics; Roche; Sanofi ; Schering-Plough; Spectrum Pharmaceuticals; SuperGen; Symphogen; Vaccinex
R. D. Baird
No relevant relationships to disclose
A. Patnaik
Research Funding - Merck
V. Moreno Garcia
No relevant relationships to disclose
K. P. Papadopoulos
Research Funding - Merck
C. R. Garrett
No relevant relationships to disclose
D. Olmos
No relevant relationships to disclose
K. A. Shannon
Employment or Leadership Position - Merck
Stock Ownership - Merck
V. Zazulina
Employment or Leadership Position - AstraZeneca
E. H. Rubin
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
I. C. Smith
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. Ryan
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
P. D. Smith
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
A. Taylor
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
M. Learoyd
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
L. Lupinacci
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
L. Yan
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
J. S. De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - AstraZeneca; Genentech; Merck Sharp & Dohme
Honoraria - AstraZeneca; Genentech; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca